Sugi Predict

Sugi Predict / Compounds / SCHEMBL3728965

SCHEMBL3728965

SCHEMBL3728965

O=C1CN(Cc2ccncc2Cc2ccccc2)C(=O)N1c1ccc(S(=O)(=O)C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 2/20 0.41
▸ ENPP2 Q13822 2/20 0.40
▸ TAS2R8 Q9NYW2 8/20 0.35
▸ NAMPT P43490 1/20 0.35
▸ PPARD Q03181 1/20 0.35
▸ PPARA Q07869 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ SCN9A Q15858 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2937811 0.91 IGF1R (0.38) IGF1RENPP2TAS2R8NAMPTPPARD
SCHEMBL2937993 0.88 IGF1R (0.40) IGF1RENPP2TAS2R8NAMPTPPARD
SCHEMBL2938324 0.88 IGF1R (0.42) IGF1RENPP2TAS2R8PPARDPPARA
SCHEMBL2931172 0.87 IGF1R (0.42) IGF1RENPP2TAS2R8NAMPTPPARD
SCHEMBL2939355 0.86 ENPP2 (0.43) IGF1RENPP2TAS2R8PPARDPPARA
SCHEMBL2938826 0.86 IGF1R (0.41) IGF1RENPP2TAS2R8PPARDPPARA
SCHEMBL17558343 0.86 PPARD (0.34) IGF1RENPP2TAS2R8NAMPTPPARD
SCHEMBL2935784 0.84 IGF1R (0.41) IGF1RENPP2TAS2R8NAMPTPPARD
SCHEMBL2940350 0.84 IGF1R (0.41) IGF1RENPP2TAS2R8NAMPTPPARD
SCHEMBL2939114 0.84 IGF1R (0.40) IGF1RENPP2TAS2R8NAMPTPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 — — US disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 — — US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 — — US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 IGF1R 1595/4885ENPP2 3905/4885TAS2R8 3914/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA IGF1R 962/4885ENPP2 3920/4885TAS2R8 4047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.